Syndax Pharmaceuticals Inc. (SNDX) reported first‑quarter 2026 financial results, posting total revenue of $64.9 million, a 224 % year‑over‑year increase from $21.3 million in Q1 2025. The company’s net loss narrowed to $42.7 million, or $0.48 per share, compared with a $84.8 million loss ($0.98 per share) in the same period a year earlier.
Revenue was driven by the two approved therapies. Revuforj generated $48.9 million in net revenue, while Niktimvo contributed $15.9 million in collaboration revenue; the partner Incyte reported $55.1 million in product revenue for the same period. The strong uptake of Revuforj in both relapsed/refractory NPM1‑mutated AML and KMT2A‑associated acute leukemia underpinned the revenue growth.
Management attributed the loss reduction to lower research and development expenses and tighter commercial spending. R&D costs fell from $30.2 million in Q1 2025 to $22.5 million in Q1 2026, while commercial expenses were trimmed by $5.3 million, allowing the company to maintain margins despite the revenue miss relative to analyst expectations of $71.8 million to $72.7 million.
Syndax reiterated its full‑year guidance, projecting operating expenses of approximately $400 million, excluding an estimated $50 million in non‑cash stock compensation. The company’s cash position of $352.1 million at March 31, 2026, provides a strong runway to reach profitability as product revenue continues to grow.
Investors reacted with caution, noting the revenue miss despite the earnings beat. The company faces headwinds from emerging competition, notably Komzifti, which received FDA approval for the same NPM1‑mutated AML population as Revuforj. Nonetheless, management expressed confidence in continued commercial growth and the long‑term potential of its flagship drugs.
Management highlighted the momentum: “We delivered over $100 million in combined Revuforj and Niktimvo net sales in the first quarter, highlighting strong demand for our medicines and advancing the company towards profitability.” “Revuforj net revenue totaled $49 million, underscoring our leadership in menin inhibition and strong adoption in both R/R NPM1m AML and KMT2Ar acute leukemia. Notably, recent analysis indicates that Revuforj is enabling nearly half of KMT2A patients to receive a stem cell transplant, providing the best chance for durable remission and positioning the franchise for long‑term growth as an increasing number of patients return to therapy post‑transplant.” “We are poised for continued commercial growth with robust prescriber bases, excellent payer coverage, and multiple evolving treatment patterns that should extend the average duration of treatment for both medicines.” “We are nearing multiple important catalysts this year, including new Revuforj data which will further highlight its best‑in‑class profile and…”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.